Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?
Table 1
Changes from pre- to posttreatment in 3 DVD parameters after 12 months of OXY-TDS treatment.
3 DVD parameters
Pretreatment
Posttreatment
Change (95% CI)
value
N
M (SD)
N
M (SD)
DUF (episodes/day)
47
9.1 (3.1)
46
7.0 (1.6)
−1.7 (−2.55;−1.15)
<0.001
NUF (episodes/night)
47
1.6 (1.4)
44
0.8 (0.8)
−0.9 (−1.12;−0.45)
<0.001
UF/24 h (episodes/day)
47
10.7 (3.9)
47
7.7 (1.8)
−2.6 (−3.50;−1.80)
<0.001
Maximum UV (ml)
38
250.7 (107.8)
39
346.0 (278.5)
63.3 (19.95; 105.85)
0.006
Nocturnal UV (ml)
38
146.6 (134.1)
39
134.2 (147.7)
−16.2 (−81.65; 48.35)
0.651
Mean UV (ml)
5
134.8 (83.4)
5
202.6 (47.9)
0.8 (−22.30; 20.70)
0.976
Urgency (episodes/day)
47
7.0 (4.7)
47
1.5 (1.5)
−4.7 (−6.05;−3.55)
<0.001
Urgency grade
47
3.7 (0.5)
44
2.3 (1.3)
−1.4 (−1.85; −0.85)
<0.001
UUI (episodes/day)
46
2.7 (2.7)
43
0.5 (0.9)
−1.9 (−2.85; −1.30)
<0.001
SUI (episodes/day)
47
0.7 (1.2)
47
0.2 (0.5)
0.0 (−0.85; 0.00)
0.007
Pad/underwear changes (number/day)
40
3.4 (4.1)
45
0.7 (1.1)
−2.2 (−2.80; −1.50)
<0.001
Liquid intake/24 h (ml)
38
1435.1 (406.1)
38
1453.5 (518.9)
15.8 (−134.15; 179.95)
0.698
Urine output/24 h (ml)
38
1385.9 (381.2)
39
1504.4 (381.1)
115.9 (0.00; 223.35)
0.054
Nocturnal urine output (ml)
37
200.8 (161.5)
38
174.7 (202.4)
−30.9 (−107.50; 34.20)
0.51
3 DVD: 3-day voiding diary; DUF: daytime urinary frequency; NUF: night-time urinary frequency; UF/24 h: 24-hour urinary frequency (total number of episodes/24 hours); SUI: stress urinary frequency; UV: urinary volume; UUI: urge urinary frequency. values: Student’s t-test or Wilcoxon signed rank test. Change: mean difference or Hodges-Lehman estimator of location shift. This variable was not reported in the 6-month visit in any of the evaluable cases. For this reason, no statistical comparisons were performed.
